Abstract
Cardiovascular disease (CVD) risk assessment is key to rational decision-making in primary prevention. The CVD risk depends on dynamic factors requiring continuous equation updates.
Design The Abu Dhabi Risk Study (ADRS) is the first and longest-duration retrospective cohort study in Abu Dhabi and the United Arab Emirates (UAE), aiming to develop 10-year risk prediction equations for CAD, stroke, and ASCVD (Atherosclerotic Cardiovascular Disease, combining CAD and stroke) and validate international risk equations.
Method The included 8699 subjects are participants of the national cardiovascular screening program of 2011-2013 with an average follow-up of 9.2 years. They were assessed retrospectively in 2023 for health outcomes. The validation cohort, 2554 subjects, is another community-based screening program done in Abu Dhabi in the period from 2016 and 2017. With an average follow-up of 6.67 years.
Results Of 8504 who were ASCVD-free, 250 had new coronary artery events. Identified risk factors for ASCVD in this population were the conventional risk factors such as age, gender, smoking, high cholesterol/HDL ratio, and diabetes diagnosis, in addition to low vitamin D level, and low glomerular filtration rate (GFR) levels.
Three ADRS prediction models were derived from Cox regression. The ADRS-CAD had a C- statistic of 0.899 compared to 0.828 of FRS (Framingham score) in the same population.
ADRS-Stroke had a c-statistic of 0.904. The ADRS-ASCVD had a c-statistic of 0.898 compared to 0.891 of PCE (pooled cohort equations) and 0.825 of FRS-CVD.
Applying the developed formulas to the validation cohort showed good predictability of CAD and ASCVD events with an ASCVD c-statistic of 0.825, for CAD the c-statistic was 0.799, and for stroke, it was 0.761. The PCE showed similar performance in this cohort with a c-statistic for ASCVD of 0.824.
Conclusion This study demonstrated the value of tailoring risk assessments to local populations and healthcare contexts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the AlAin Human Ethics Committee, approval number 13/58, and Ambulatory Healthcare Services IRB 19-2022. All methods were carried out under relevant guidelines and regulations. The authors confirm that the study was conducted in accordance with the Helsinki Declaration. Consent statement in the Ethics approval and consent to participate: Informed consent was waived by the IRBs as the study was designed for retrospective data gathered as part of patient care and anonymized at analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Tables were added to the main manuscript and Co-Authors with significant contributions were added. Order of co-authors updated
Data Availability
Data availability is restricted due to institution policies.
